Strong demand for cardiac devices drives Medtronic (MDT.US) to exceed Q1 expectations and raise its full-year guidance; invests $700 million to boost its robotic surgery business

```htmlAccording to Zhitong Finance APP, before the U.S. stock market opened on Tuesday, medical device manufacturer Medtronic (MDT.US) announced better-than-expected results for the first quarter of fiscal year 2027 and raised its full-year guidance, betting on strong demand for its heart devices used in complex cardiovascular surgeries. At the time of writing, Medtronic shares were up more than 3% in pre-market trading on Tuesday.```